1241833-34-0Relevant academic research and scientific papers
Design, synthesis, and in?vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition
Oleksak, Patrik,Psotka, Miroslav,Vancurova, Marketa,Sapega, Olena,Bieblova, Jana,Reinis, Milan,Rysanek, David,Mikyskova, Romana,Chalupova, Katarina,Malinak, David,Svobodova, Jana,Andrys, Rudolf,Rehulkova, Helena,Skopek, Vojtech,Ngoc Lam, Pham,Bartek, Jiri,Hodny, Zdenek,Musilek, Kamil
, p. 410 - 424 (2021/02/05)
Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel co
Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein
-
Page/Page column 226-227; 231-234, (2019/02/14)
In one aspect, the invention relates to substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the com
NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
-
Page/Page column 55; 56; 84, (2014/01/07)
The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules
Fletcher, Steven,Page, Brent D.G.,Zhang, Xialoei,Yue, Peibin,Li, Zhi Hua,Sharmeen, Sumaiya,Singh, Jagdeep,Zhao, Wei,Schimmer, Aaron D.,Trudel, Suzanne,Turkson, James,Gunning, Patrick T.
, p. 1459 - 1470 (2012/07/01)
More than 50 new inhibitors of the oncogenic Stat3 protein were identified through a structure-activity relationship (SAR) study based on the previously identified inhibitor S3I-201 (IC50=86μM, Ki>300μM). A key structural feature of
